# PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

> **NCT07277842** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 382 (estimated)

## Conditions studied

- Locally Advanced Low Rectal Adenocarcinoma
- pMMR (Microsatellite Stable Rectal Cancer)

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** FOLFOXIRI chemotherapy
- **DRUG:** CAPOX chemotherapy
- **RADIATION:** Long-course pelvic radiotherapy

## Key facts

- **NCT ID:** NCT07277842
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2028-12-29
- **Final completion:** 2028-12-29
- **Target enrollment:** 382 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07277842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07277842, "PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07277842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*